These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Conformal radiotherapy for patients with clinical stage T1-T3 prostate cancer].
    Author: Majewski W, Miszczyk L, Zajusz A.
    Journal: Przegl Lek; 2004; 61(5):503-8. PubMed ID: 15515815.
    Abstract:
    PURPOSE: The purpose of the study is the evaluation of the efficacy and morbidity of conformal radiotherapy in patients with clinical stage T1-T3 prostate cancer. MATERIAL AND METHODS: The study group comprises 71 patients with clinical stage T1-T3, N0, M0 prostate cancer, treated with conformal radiotherapy between 1998 and 2000. The planned target volume included in all patients prostate a margin (PTV1). Forty patients (56%) were initially irradiated for the pelvic region (PTV2). The mean total radiation dose delivered to prostate was 68 Gy, and to the pelvis--44 Gy. Radiation morbidity was scored by the RTOG/EORTC system, and it was analysed in relation to the total dose. The 2-year biochemical relapse-free survival and 2-year metastatic control rates were compared by clinical T-stage and histologic grade. The probability of biochemical relapse and the probability of distant metastases were estimated as a function of clinical T-stage, histologic grade, the planned target volume (PTV1 vs PTV1+PTV2) and total radiation dose. RESULTS: There were no acute > or = grade III bladder toxicity, and only 3 patients (4%), who were irradiated for the pelvis had acute grade III bowel toxicity. No patient had late grade > or = III toxicity. The actual 2-year biochemical relapse-free survival and 2-year metastatic control according to T-stage were respectively: T1c--89% and 100%, T2a--90% and 100%, T2b--77% and 85%, T2c--62% and 83%, T3--58% and 65%, and by histologic grade they were respectively: G1--100% and 100%, G2--79% and 96%, G3--36% and 50%. Statistically significant relationships were found between the probability of distant metastases or biochemical relapse and histologic grade (p<0.00, p=0.005). Clinical T-stage had significant influence on the probability of distant metastases and borderline influence on the probability of biochemical relapse (p=0.004 and p=0.056). In the multivariate analysis, only histologic grade remained significant. CONCLUSIONS: Conformal radiotherapy for prostate cancer is well tolerated, and it yields satisfactory results which depend on histologic grade and clinical T-stage.
    [Abstract] [Full Text] [Related] [New Search]